Overview

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to investigate the safety and tolerability of AZD0328 following once-daily dosing for 13 days in elderly healthy volunteers and to define maximum tolerated dose.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca